Bavencio (avelumab) is an antibody pharmaceutical. Avelumab was first approved as Bavencio on 2017-03-23. It is used to treat merkel cell carcinoma and transitional cell carcinoma in the USA. It has been approved in Europe to treat neuroendocrine tumors. The pharmaceutical is active against programmed cell death 1 ligand 1.
|Indication||merkel cell carcinoma, neuroendocrine tumors, transitional cell carcinoma|
|Drug Class||Monoclonal antibodies: fully human, immunomodulating|